15. Inclusion body myositis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04789070 (ClinicalTrials.gov) | January 1, 2022 | 15/2/2021 | Phase III Trial of Sirolimus in IBM | A Double-Blind Randomised Controlled Trial (dbRCT) Phase III Trial Investigating the Effect of Sirolimus on Disease Progression in Patients With Inclusion Body Myositis (IBM) as Measured by the IBM Functional Rating Scale (IBM-FRS) | Inclusion Body Myositis | Drug: Sirolimus;Drug: Placebo | University of Kansas Medical Center | The Perron Institute | Not yet recruiting | 45 Years | N/A | All | 140 | Phase 3 | United States |
| 2 | NCT02481453 (ClinicalTrials.gov) | July 15, 2015 | 13/5/2015 | Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis | Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI | Inclusion Body Myositis (IBM) | Drug: Rapamycin;Drug: Placebo | Institut National de la Santé Et de la Recherche Médicale, France | NULL | Completed | 45 Years | 85 Years | All | 44 | Phase 2/Phase 3 | France |